ADC冰火交融:映恩、乐普、恒瑞等再获进展,默沙东、BMS选择性撤退撤退

医药经济报
27 Apr

近日,乐普生物宣布,其EGFR靶向抗体偶联药物(ADC)MRG003治疗复发性或转移性鼻咽癌(R/M NPC)的关键IIb期研究数据入选美国临床肿瘤学会(ASCO)年会“重磅研究摘要(LBA)”,将以口头报告形式亮相。目前MRG003已经在国内上市审核阶段,并被纳入优先审评,有望成为全球首款获批上市的EGFR ADC。值得一提的是,此前ADC明星企业映恩生物港交所上市首日大涨116%。并在4月25...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10